Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension.[1] It is an activin signaling inhibitor,[1] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc).[2] It is given by subcutaneous injection.[1]
Sotatercept was approved for medical use in the United States in March 2024.[1][3][4]
^ abcde"Winrevair- sotatercept-csrk kit". DailyMed. 26 March 2024. Archived from the original on 25 April 2024. Retrieved 25 April 2024.
^Doggrell, Sheila A (July 2023). "Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?". Expert Opinion on Biological Therapy. 23 (7): 589–593. doi:10.1080/14712598.2023.2221784. PMID 37269300.
^"Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
^"FDA Approves Merck's Winrevair (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)" (Press release). Merck. 27 March 2024. Archived from the original on 27 March 2024. Retrieved 27 March 2024 – via Business Wire.
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. It is an activin signaling...
and one in preclinical development. Luspatercept (ACE-536) for anemia Sotatercept (ACE-011) for pulmonary arterial hypertension Dalantercept (ACE-041)...
test". Many have no data on mortality benefit or time to progression. Sotatercept (Winrevair) was approved for medical use in the United States in March...
Jurcic, Joseph G; Sekeres, Mikkael A; Berdeja, Jesus; et al. (2018). "Sotatercept with long-term extension for the treatment of anaemia in patients with...
Global Information